More than a year after the FDA approved Satsuma’s Atzumi (STS 101) intranasal dry powder dihydroergotamine for the treatment of migraine in adults, Satsuma parent company SNBL says that it is still trying to find a partner to commercialize the product in the US.
According to SNBL, “due to Atzumi being positioned as a second-line treatment for acute migraine, and its nature as a drug-device combination product, Satsuma has not yet been able to reach agreement with partners under the terms that meet the Company’s expectations.” The company says that it has now turned to Trinity Life Sciences to help SNBL explore more creative strategies for bringing Atzumi to market.
The company says that it still believes in the commercial viability of the product, in part because “Only Atzumi incorporates the Company’s proprietary advanced powder and device technology, SMART (Simple MucoAdhesive Release Technology), designed to make dihydroergotamine more accessible to people with migraine.”
While it is working to get the nasal powder into the US market, SNBL says, the company believes that “by enabling Satsuma to proactively enhance manufacturing and commercialization framework, while concurrently pursuing partnering opportunities outside the United States, can lead to realize and increase the Atzumi’s value earlier.”
Read the SNBL announcement (translated from Japanese)
